Global Hyperuricemia API Manufacturers, Marketed and Phase III Drugs Landscape, 2018-2020 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 6, 2018--The “Hyperuricemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Hyperuricemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018′ report provides comprehensive insights about marketed and Phase III products for Hyperuricemia . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Coverage of API manufacturers for Hyperuricemia marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.
This report provides a comprehensive understanding of the emerging Phase III therapies for Hyperuricemia which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
Key Topics Covered:
1. Report Introduction2. Hyperuricemia: Overview3. Comparative Analysis of Marketed and Emerging Products4. Marketed Therapies
5. Emerging Therapies (Phase III)For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gbth8z/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005894/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/06/2018 03:37 PM/DISC: 09/06/2018 03:37 PM